Gestational diabetes & diabetes in pregnancy

Early Metformin in Gestational Diabetes: A Randomized Clinical Trial

JAMAPublished Randomised controlled trial

Authors' conclusion

Early treatment with metformin was not superior to placebo for the composite primary outcome. Prespecified secondary outcome data support further investigation of metformin in larger clinical trials.

Study context

Population
Individuals with GDM by World Health Organization 2013 criteria, 2 centres in Ireland (one tertiary, one smaller regional hospital); enrolled June 2017–September 2022; mean age 34.3 years535 pregnancies randomized
Participants
510 individuals
Comparison
Early metformin vs placebo, in addition to usual care
Primary endpoint
Composite of:
  • Insulin initiation
  • Fasting glucose ≥5.1 mmol/L
Follow-up
Gestation weeks 32 or 38
Methodological detailsdouble-blind, placebo-controlled, 2 centres, Followed up until 12 weeks' postpartum
  • Double-blind
  • Placebo-controlled
  • 2 centres
  • Followed up until 12 weeks' postpartum

Primary result

As reported in the abstract

Each group vs placeboBetween-group difference (95% CI)P value
Metformin
−6.9%(−15.1% to 1.4%)
P = 0.13
Each group vs placeboRelative risk (95% CI)P value
Metformin
0.89(0.78–1.02)
P = 0.13

Secondary outcomes

Prespecified secondary maternal outcomes

Of 6 prespecified secondary maternal outcomes, 3 favored metformin: time to insulin initiation, self-reported capillary glycemic control and gestational weight gain
3 of 6

Secondary neonatal outcomes: neonatal size

Smaller neonates with metformin: lower mean birth weights, lower proportion >4 kg, lower proportion >90% percentile, smaller crown-heel length

Safety

Neonatal complications

No differences in neonatal intensive care needs, respiratory distress requiring respiratory support, jaundice requiring phototherapy, major congenital anomalies, neonatal hypoglycemia, or 5-minute Apgar <7

Original publication

Early Metformin in Gestational Diabetes: A Randomized Clinical Trial. JAMA. Published 24 October 2023. doi:10.1001/jama.2023.19869

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.